Factor IX Deficiency Treatment (Hemophilia B) Market Size, Share and Growth Outlook, 2026

Factor IX Deficiency Treatment (Hemophilia B) Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Factor IX Deficiency Treatment (Hemophilia B) Market size is forecast to increase from $5.58 Billion in 2026 to $9.88 Billion in 2034 at a CAGR of 7.4% between 2026 and 2034.

The Factor IX Deficiency Treatment (Hemophilia B) market report provides detailed analysis and outlook of Factor IX Deficiency Treatment (Hemophilia B) segments including By Therapy Type (Factor IX Replacement Therapy, Gene Therapy, Non-Factor Replacement Therapy), By Product Type (Recombinant Factor IX, Plasma-Derived Factor IX, Prothrombin Complex Concentrates ), By Treatment Regimen (Prophylaxis Treatment, On-Demand ), By Patient Category (Adult Patients, Pediatric Patients), By End-User (Specialized Hemophilia Treatment Centers, Hospitals and Clinics, Home Healthcare Settings) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Factor IX Deficiency Treatment (Hemophilia B) Industry Overview: Gene Therapy Stabilization and Precision Factor Replacement Optimization

CSL Behring Gene Therapy Demonstrating Sustained Factor IX Expression and Reduced Prophylaxis Burden

The Factor IX deficiency treatment (Hemophilia B) industry is advancing through long-term validation of gene therapy approaches aimed at reducing dependence on recurrent Factor IX concentrate infusions. In May 2026, CSL Behring reported sustained and stable Factor IX activity levels in patients enrolled in its hemophilia B gene therapy clinical program. These findings reinforce the clinical viability of single-infusion gene therapy as a transformative approach, significantly lowering the requirement for routine prophylactic Factor IX replacement. The persistence of therapeutic protein expression is strengthening the position of gene therapy as a durable treatment strategy in bleeding disorder management.

Expanded Pediatric Labeling Enhancing Prophylactic Transition Strategies in Recombinant Factor IX Therapy

In March 2026, the U.S. FDA approved updated labeling for recombinant Factor IX products to include expanded pediatric dosing data. These revisions provide more precise clinical guidance for transitioning younger patients from on-demand treatment to prophylactic regimens. The updated dosing frameworks aim to reduce spontaneous and trauma-induced bleeding episodes, particularly joint bleeds that contribute to long-term arthropathy. The enhancement of pediatric-specific dosing recommendations is improving early intervention strategies and supporting standardized prophylaxis adoption in hemophilia B care pathways.

Molecular Risk Stratification Tools Reducing Inhibitor Development in Factor IX Therapy

Research published in the Journal of Thrombosis and Haemostasis in 2026 highlights advanced molecular approaches for predicting and managing inhibitor development in patients receiving Factor IX replacement therapy. The study introduces diagnostic algorithms that assess patient-specific immunological risk profiles prior to initiating concentrate-based treatment plans. These tools enable clinicians to identify individuals at higher risk of neutralizing antibody formation, allowing for more tailored therapeutic selection. The integration of predictive immunological modeling is strengthening personalized treatment planning and improving safety outcomes in Factor IX deficiency management.

Factor IX Deficiency Treatment (Hemophilia B) Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Factor IX Deficiency Treatment (Hemophilia B) market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- CSL Behring LLC, Sanofi S.A., Pfizer Inc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Biogen Inc., Swedish Orphan Biovitrum AB (Sobi), Medexus Pharmaceuticals Inc., Octapharma AG, Grifols, S.A.. The Factor IX Deficiency Treatment (Hemophilia B) market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Factor IX Deficiency Treatment (Hemophilia B) industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Factor IX Deficiency Treatment (Hemophilia B) Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Factor IX Deficiency Treatment (Hemophilia B) companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Factor IX Deficiency Treatment (Hemophilia B) markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Factor IX Deficiency Treatment (Hemophilia B) Market Competitive Benchmarking and Company Analysis

Leading companies in Factor IX Deficiency Treatment (Hemophilia B) industry include- CSL Behring LLC, Sanofi S.A., Pfizer Inc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Biogen Inc., Swedish Orphan Biovitrum AB (Sobi), Medexus Pharmaceuticals Inc., Octapharma AG, Grifols, S.A.. The Factor IX Deficiency Treatment (Hemophilia B) market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Factor IX Deficiency Treatment (Hemophilia B) Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Factor IX Deficiency Treatment (Hemophilia B) market remains one of the strongest-performing segments in the country.
The US Factor IX Deficiency Treatment (Hemophilia B) Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Factor IX Deficiency Treatment (Hemophilia B) market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Factor IX Deficiency Treatment (Hemophilia B) industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Factor IX Deficiency Treatment (Hemophilia B) markets

Canada's strong Factor IX Deficiency Treatment (Hemophilia B) sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Factor IX Deficiency Treatment (Hemophilia B) market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Factor IX Deficiency Treatment (Hemophilia B) Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Factor IX Deficiency Treatment (Hemophilia B) market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Factor IX Deficiency Treatment (Hemophilia B) population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Factor IX Deficiency Treatment (Hemophilia B) industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Factor IX Deficiency Treatment (Hemophilia B) market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Factor IX Deficiency Treatment (Hemophilia B) sales through 2034

France Factor IX Deficiency Treatment (Hemophilia B) companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Factor IX Deficiency Treatment (Hemophilia B) Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Factor IX Deficiency Treatment (Hemophilia B) distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Factor IX Deficiency Treatment (Hemophilia B) Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Factor IX Deficiency Treatment (Hemophilia B) market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Factor IX Deficiency Treatment (Hemophilia B) industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Factor IX Deficiency Treatment (Hemophilia B) industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Factor IX Deficiency Treatment (Hemophilia B) Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Factor IX Deficiency Treatment (Hemophilia B) market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Factor IX Deficiency Treatment (Hemophilia B) market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Factor IX Deficiency Treatment (Hemophilia B) Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Factor IX Deficiency Treatment (Hemophilia B) Market Segmentation

By Therapy Type
Factor IX Replacement Therapy
Gene Therapy
Non-Factor Replacement Therapy
By Product Type
Recombinant Factor IX
Plasma-Derived Factor IX
Prothrombin Complex Concentrates
By Treatment Regimen
Prophylaxis Treatment
On-Demand
By Patient Category
Adult Patients
Pediatric Patients
By End-User
Specialized Hemophilia Treatment Centers
Hospitals and Clinics
Home Healthcare Settings

Top Companies in Factor IX Deficiency Treatment (Hemophilia B) Industry

CSL Behring LLC
Sanofi S.A.
Pfizer Inc.
Takeda Pharmaceutical Company Limited
Novo Nordisk A/S
Biogen Inc.
Swedish Orphan Biovitrum AB (Sobi)
Medexus Pharmaceuticals Inc.
Octapharma AG
Grifols, S.A.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025